+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Survival for older patients with acute myeloid leukemia: a population-based study.


      Adult, epidemiology, United States, Survival Rate, SEER Program, Retrospective Studies, Prognosis, Neoplasm Staging, pathology, drug therapy, Neoplasm Recurrence, Local, Middle Aged, Male, therapy, mortality, Leukemia, Myeloid, Acute, Humans, Follow-Up Studies, Female, Combined Modality Therapy, Aged, 80 and over, Aged

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Acute myeloid leukemia is the second most common leukemia among United States adults with a median age of 69 years. We investigated recent clinical practices related to treatments and disease outcomes in older patients with acute myeloid leukemia in the United States. In this retrospective cohort study, we used Surveillance, Epidemiology, and End Results program data from 2000 through 2007 linked to Medicare enrollment and utilization data in the United States. Among 5,480 patients with acute myeloid leukemia (median age 78 years, range 65-93), 38.6% received leukemia therapy within three months of diagnosis (treated group). Practice changed with 16.3% of treated patients receiving hypomethylating agents after 2004 when those agents became available. Median survival was two months in the untreated group versus six months in the treated group (P<0.01) with the biggest improvements seen in those aged 65-69 years (10 months vs. 4 months; P<0.01) and 70-74 years (8 months vs. 3 months; P<0.01). In 46 patients receiving allogeneic hematopoietic cell transplantation (0.8%), the median survival from diagnosis was 22 months. Therapy for leukemia improves overall survival in older acute myeloid leukemia patients. Based on their comorbidities, most patients up to 80 years of age should be considered for treatment. New therapies including hypomethylating agents and allogeneic hematopoietic cell transplantation are promising and must be compared with other chemotherapy regimens.

          Related collections

          Author and article information



          Comment on this article